Get the Stockscreener App
6.6167
3.93%
-0.2533
Immuneering Corp stock is traded at $6.6167, with a volume of 888.21K.
It is down -3.93% in the last 24 hours and up +9.09% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$6.87
Open:
$6.75
24h Volume:
888.21K
Relative Volume:
0.53
Market Cap:
$274.99M
Revenue:
$317.00K
Net Income/Loss:
$-53.47M
P/E Ratio:
-3.5009
EPS:
-1.89
Net Cash Flow:
$-49.31M
1W Performance:
+4.76%
1M Performance:
+9.09%
6M Performance:
+432.26%
1Y Performance:
+252.94%
1-Day Range:
$6.51
$7.15
1-Week Range:
$6.10
$7.15
52-Week Range:
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
6.615 | 434.45M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.99 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.78 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Initiated | Leerink Partners | Outperform |
| Dec-13-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-15-24 | Reiterated | Needham | Buy |
| Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-01-23 | Initiated | Needham | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
| Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-30-23 | Initiated | Mizuho | Neutral |
| Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-01-22 | Initiated | Oppenheimer | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
Best data tools to analyze Immuneering Corporation stockAnalyst Upgrade & Free High Accuracy Swing Entry Alerts - newser.com
Is Immuneering Corporation stock undervalued vs historical averagesTrade Signal Summary & Free Fast Gain Swing Trade Alerts - newser.com
Is Immuneering Corporation stock positioned well for digital economyGap Up & Entry Point Strategy Guides - newser.com
What indicators show strength in Immuneering CorporationWeekly Loss Report & Accurate Intraday Trading Signals - newser.com
Can momentum traders help lift Immuneering CorporationPortfolio Value Summary & Stepwise Swing Trade Plans - newser.com
Immuneering (NASDAQ:IMRX) Upgraded at Leerink Partnrs - MarketBeat
Trend analysis for Immuneering Corporation this week2025 Retail Activity & Risk Controlled Daily Trade Plans - newser.com
Leerink Partners Initiates Coverage on Immuneering (NASDAQ:IMRX) - MarketBeat
Can Immuneering Corporation stock sustain institutional interestM&A Rumor & Long-Term Safe Return Strategies - newser.com
Top chart patterns to watch in Immuneering CorporationMarket Trend Review & Community Shared Stock Ideas - newser.com
What’s the recovery path for long term holders of Immuneering CorporationWeekly Stock Summary & Risk Adjusted Buy and Sell Alerts - newser.com
This Immuneering Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Published on: 2025-10-31 05:51:06 - newser.com
Will Immuneering Corporation stock outperform value stocksQuarterly Risk Review & Daily Price Action Insights - newser.com
How Immuneering Corporation stock valuations compare to rivals2025 Big Picture & Fast Gaining Stock Reports - newser.com
How to build a dashboard for Immuneering Corporation stock2025 Earnings Surprises & Technical Buy Zone Confirmations - newser.com
Is Immuneering Corporation stock ready for a breakout2025 Price Targets & Risk Controlled Daily Plans - newser.com
Will Immuneering Corporation stock benefit from automationJuly 2025 Volume & Daily Entry Point Alerts - newser.com
Has Immuneering Corporation formed a bullish divergence2025 Top Gainers & Technical Confirmation Trade Alerts - newser.com
Can Immuneering Corporation rally from current levelsJuly 2025 Decliners & Growth Oriented Trading Recommendations - newser.com
Can machine learning forecast Immuneering Corporation recoveryJuly 2025 Weekly Recap & High Accuracy Investment Signals - newser.com
How strong is Immuneering Corporation stock balance sheetJuly 2025 Setups & Expert Verified Stock Movement Alerts - newser.com
Is Immuneering Corporation stock attractive for growth ETFsJuly 2025 Final Week & Consistent Growth Equity Picks - fcp.pa.gov.br
What institutional flow reveals about Immuneering CorporationForecast Cut & Capital Efficient Trade Techniques - newser.com
Forecasting Immuneering Corporation price range with options dataMarket Activity Summary & Daily Profit Maximizing Trade Tips - newser.com
Can Immuneering Corporation stock withstand economic slowdownJuly 2025 Action & Free Growth Oriented Trading Recommendations - newser.com
Regression analysis insights on Immuneering Corporation performance2025 Macro Impact & AI Driven Stock Movement Reports - newser.com
Weiss Ratings Reiterates "Sell (E+)" Rating for Immuneering (NASDAQ:IMRX) - MarketBeat
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):